A potentially game-changing antiviral treatment for COVID-19 that can be administered orally early on, and potentially head off much more serious cases, is set to be licensed for generic production in most low- and middle-income countries (LMICs), in an unprecedented breakthrough in access to a new COVID treatment.   The historic deal, reached between the pharma […] Continue reading ->
Africans are a step closer to speedier access to newer, safer medicines following this week’s notification by 15 African Union (AU) member countries that they have formally ratified and deposited their accord to create a new African Medicines Agency (AMA). Although the AU adopted the treaty to set up the AMA back in February 2019, […] Continue reading ->
Indian generic drug manufacturers are poised to make the antiviral pill, molnupiravir, which halved hospitalisations in a trial of high-risk people with COVID-19. Merck, which developed molnupiravir in collaboration with Ridgeback Biotherapeutics, has awarded non-exclusive, voluntary licensing agreements to eight generic companies in India since April in anticipation of positive trial results. According to Merck, […] Continue reading ->
CAPE TOWN – A drug discovery and development centre based at the University of Cape Town (UCT) has joined forces with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to strengthen health innovation in Africa. The three-year partnership announced this week will focus on driving capacity-strengthening for drug discovery and development in Africa by […] Continue reading ->
In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading ->
Despite growing awareness of the urgent threat of antibiotic resistance, the world is still failing to develop needed antibacterial treats, according to a new report by the World Health Organization (WHO).  Of the 43 antibiotics and 27 non-traditional antibacterial agents in the current clinical antibacterial pipeline, none is sufficient to tackle the challenge of increasing […] Continue reading ->